Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Oct 15, 2018 (filed on Oct 19, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:80,000Price:$0.08
- Oct 15, 2018 (filed on Oct 19, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,973,333Price:$0.08
- Oct 11, 2018 (filed on Oct 23, 2018)Insider Name:Abeles John HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:266,667Price:$0.08
- Aug 13, 2018 (filed on Oct 23, 2018)Insider Name:Abeles John HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:40,000Price:--
- Jul 27, 2018 (filed on Jul 30, 2018)Insider Name:Von Rump Stephen L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:133,333Price:$0.08
- Jul 25, 2018 (filed on Jul 30, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,100,000Price:$0.08
- Jul 20, 2018 (filed on Jul 20, 2018)Insider Name:Von Rump Stephen L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- Jul 09, 2018 (filed on Jul 12, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:400,000Price:$0.08
- Jul 09, 2018 (filed on Jul 12, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:6,933,333Price:$0.08
- Jul 03, 2018 (filed on Jul 10, 2018)Insider Name:Abeles John HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:400,000Price:$0.08
Filings by filing date
- Oct 11, 2018 (filed on Oct 23, 2018)Insider Name:Abeles John HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:266,667Price:$0.08
- Aug 13, 2018 (filed on Oct 23, 2018)Insider Name:Abeles John HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:J - Other transaction# or value acquired/disposed of:40,000Price:--
- Oct 15, 2018 (filed on Oct 19, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:80,000Price:$0.08
- Oct 15, 2018 (filed on Oct 19, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:8,973,333Price:$0.08
- Jul 25, 2018 (filed on Jul 30, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,100,000Price:$0.08
- Jul 27, 2018 (filed on Jul 30, 2018)Insider Name:Von Rump Stephen L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:133,333Price:$0.08
- Jul 20, 2018 (filed on Jul 20, 2018)Insider Name:Von Rump Stephen L.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
- Jul 09, 2018 (filed on Jul 12, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:400,000Price:$0.08
- Jul 09, 2018 (filed on Jul 12, 2018)Insider Name:Lewis William Austin IVOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:6,933,333Price:$0.08
- Jul 03, 2018 (filed on Jul 10, 2018)Insider Name:Abeles John HOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:400,000Price:$0.08
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 414 N Orleans St Ste 502 CHICAGO IL 60654-4498 |
Tel: | N/A |
Website: | https://www.medite-group.com |
IR: | See website |
Key People | ||
W. Austin Lewis Chairman of the Board | Elmar A. Dave Chief Executive Officer | Gary D. Pickett Chief Financial Officer |
Michaela Ott Chief Operating Officer | Jeff Rencher Chief Marketing and Business Development Officer |
Business Overview |
MEDITE Cancer Diagnostics, Inc. (MEDITE), formerly CytoCore, Inc., is a medical technology company engaged in the development, engineering, manufacturing and marketing of molecular biomarkers and medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions and related diseases. The Company develops, manufactures and sells a range of laboratory devices and consumable supplies for its target market in the histology and cytology cancer diagnostics segment. The Company offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis. The Company offers USE33, an ultrasonic decalcification instrument that runs the process under controlled temperatures. The Company also offers TPC15 Duo or Trio, TES99, TES Valida, M530, A550, M380, TST44 and COT20 linear staining systems. In addition, the Company also offers RCM9000, ACS720 and TWISTER glass and robotic coverslippers. |
Financial Overview |
For the nine months ended 30 September 2018, Medite Cancer Diagnostics Inc revenues increased 27% to $6.2M. Net loss applicable to common stockholders decreased 35% to $2.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development, decrease of 40% to $705K (expense), Selling decrease of 7% to $3M (expense). |
Employees: | 5 as of Mar 27, 2014 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8.39M as of Sep 30, 2018 |
Annual revenue (TTM): | $8.13M as of Sep 30, 2018 |
EBITDA (TTM): | -$3.73M as of Sep 30, 2018 |
Net annual income (TTM): | -$5.42M as of Sep 30, 2018 |
Free cash flow (TTM): | -$5.30M as of Sep 30, 2018 |
Net Debt Last Fiscal Year: | $5.65M as of Sep 30, 2018 |
Shares outstanding: | 86,723,700 as of Nov 10, 2018 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |